» Articles » PMID: 25188366

Risks for Multidrug-resistant Pathogens in the ICU

Overview
Specialty Critical Care
Date 2014 Sep 5
PMID 25188366
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: The impact of multidrug-resistant organisms (MDROs) is rising and often underestimated. The epidemiology of MDROs is extremely complex and multifactorial. There is increasing antibiotic resistance, mainly related to antibiotic pressure and patients' characteristics.

Recent Findings: Emphasis on MDRO epidemiology is needed to better understand current strategies of prevention and management. Among them, antibiotic stewardship has been one of the most successful strategies. It is important to note that there is a controversial issue when considering community and healthcare-related infections. In addition, different strategies have been determined to find the impact and optimal use of recently launched antibiotics for MDRO treatment.

Summary: Infections with MDROs can prolong hospital stay, promote antibiotic use and prolong duration of mechanical ventilation. Some points should be further explored in clinical research such as the heterogeneity of healthcare-associated pneumonia and the need of new drug development. Resistance to non fermentative Gram-negative bacilli, rising minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus and spread of MDROs in patients without known risk factors suggest a review of guideline validation, taking into account ecology and severity of patient illness to provide timely and appropriate empiric therapy.

Citing Articles

Advancing understanding and management of invasive fungal diseases in the intensive care unit: Insights from FUNDICU consensus definitions.

Martin-Loeches I J Intensive Med. 2024; 4(4):482-483.

PMID: 39310057 PMC: 11411431. DOI: 10.1016/j.jointm.2024.06.001.


Demographic Characteristics and Economic Burden of Infection in Korea: A Nationwide Population-Based Study after Propensity Score Matching.

Cha J, Yoon J, Kwak M, Lee M, Cho Y Antibiotics (Basel). 2024; 13(6).

PMID: 38927208 PMC: 11201190. DOI: 10.3390/antibiotics13060542.


A comparative study on the use of procalcitonin to distinguish between central fever and infectious causes of fever.

Khanum I, Shoaib M, Awan S Pan Afr Med J. 2024; 47:43.

PMID: 38681106 PMC: 11055181. DOI: 10.11604/pamj.2024.47.43.37617.


Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections....

Gatti M, Rinaldi M, Tonetti T, Siniscalchi A, Viale P, Pea F Antibiotics (Basel). 2023; 12(10).

PMID: 37887225 PMC: 10604776. DOI: 10.3390/antibiotics12101524.


Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit.

Pace M, Corrente A, Passavanti M, Sansone P, Petrou S, Leone S World J Clin Cases. 2023; 11(13):2874-2889.

PMID: 37215420 PMC: 10198073. DOI: 10.12998/wjcc.v11.i13.2874.